Heart transplantation: A thirty-year perspective

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 189-205

  Miniati, Douglas N ^a   Robbins, Robert C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Immunosuppression; Indications; Surgery; Treatment

Indexed keywords

AZATHIOPRINE; CD18 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ALGORITHM; BONE MARROW SUPPRESSION; CANCER RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG TOXICITY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTORY OF MEDICINE; HUMAN; HYPERLIPIDEMIA; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; ORGAN DONOR; OSTEOPOROSIS; PATIENT SELECTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SURGICAL ANATOMY; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

CAUSE OF DEATH; FORECASTING; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); POSTOPERATIVE COMPLICATIONS; TISSUE DONORS;

EID: 0036178087     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.104050     Document Type: Review

References (68)

1. Thirty years of cardiac transplantation at Stanford University
2. The transplantation of veins and organs
3. Practical methods of homologous cardiac transplantation
4. Heart excision and replacement
5. Homotransplantation of the dog heart
6. Transplantation of the homologous canine heart
7. Complete homologous heart transplantation
8. Complete homotransplantation of canine heart and lungs
9. Homovital transplantation of the heart
10. Studies on orthotopic transplantation of the canine heart
11. The operation. A human cardiac transplant: An interim report of a successful operation performed at Groote Schuur Hospital, Cape Town
12. Surgical aspects of cardiac transplantation in man
13. Determinants of operative risk in human heart transplantation
14. Transvenous biopsy from canine orthotopic heart allografts
15. Use of rabbit antithymocyte globulin in cardiac transplantation. Relationship of serum clearance rates to clinical outcome
16. Cardiac homotransplantation
17. The registry of the International Society for Heart and Lung Transplantation: Seventeenth official report - 2000
18. Cardiac transplantation in man. 3. Surgical aspects
19. What we have learned about heart transplants
20. Unique aspects of heart and lung transplantation exhibited in the "domino-donor" operation
21. An alternative technique for orthotopic cardiac transplantation, with preservation of the normal anatomy of the right atrium
22. Recent developments in lung and heart-lung transplatation
23. Total orthotopic heart transplantation: An alternative to the standard technique
24. Techniques in orthotopic cardiac transplantation: A review
25. Orthotopic cardiac transplantation technique: A survey of current practice
26. Transplant candidates with severe left ventricular dysfunction managed with medical treatment: Characteristics and survival
27. Clinical status of patients removed from a transplant waiting list rivals that of transplant recipients at significant cost savings
28. The alternate recipient list for heart transplantation: A model for expansion of the donor pool
29. Heart transplantation in patients seventy years of age and older: A comparative analysis of outcome
30. 24th Bethesda conference: Cardiac transplantation. Task Force 2: Donor guidelines
31. Transforming the "unacceptable" donor: Outcomes from the adoption of a standardized donor management technique
32. Extension of donor criteria in cardiac transplantation: Surgical risk versus supply-side economics
33. Outcomes of patients undergoing transplantation with older donor hearts
34. The use of advanced-age donor hearts adversely affects survival in pediattic heart transplantation
35. Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation
36. Inhaled nitric oxide for right ventricular dysfunction following cardiac transplantation
37. Extracorporeal pulsatile biventricular support after cardiac transplantation
38. Right ventricular assist and prostacyclin infusion for allograft failure in the presence of high pulmonary vascular resistance
39. Extracorporeal life support after heart or lung transplantation
40. ECMO and inhaled nitric oxide for cardiopulmonary failure after heart retransplantation
41. Advances in immunosuppression for heart transplantation
42. European Multicenter Tacrolimus (FK506) Heart Pilot Study: One-year results - European Tacrolimus Multicenter Heart Study Group
43. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients
44. New immunosuppressive agents in clinical use: Mycophenolate mofetil and tacrolimus
45. Cytolytic induction therapy in heart and lung transplantation: The protagonist opinion
46. Antilymphocyte-antibody prophylaxis: Review of the adult experience in heart transplantation
47. Risk factors for late recurrent rejection after heart transplantation: A multiinstitutional, multivariable analysis
48. Elevated serum concentrations of cardiac troponin T in acute allograft rejection after human heart transplantation
49. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group
50. Recurrent or persistent cardiac allograft rejection: Therapeutic options and recommendations
51. The repetitive histologic pattern of vascular cardiac allografi rejection. Increased incidence associated with longer exposure to prophylactic murine monoclonal anti-CD3 antibody (OKT3)
52. Additional strategies for immunosuppression
53. Individualizing immunosuppression for heart transplantation: Strategies for the next decade
54. Cardiac allograft vasculopathy - A changing perspective
55. Allograft coronary artery disease: Clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection
56. Cardiac allograft vasculopathy
57. Intravascular ultrasound for assessment of coronary allografi vasculopathy
58. Revascularization procedures in patients with transplant coronary artery disease
59. Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease
60. Coronary artery bypass grafting after orthotopic heart transplantation
61. Cardiac allograft vasculopathy - Coronary interventions and surgical options
62. Superior vena cava syndrome after heart transplantation: Percutaneous treatment of a complication of bicaval anastomoses
63. Severe tricuspid regurgitation after heart transplant
64. Cardiac transplantation and related infections
65. Tumors after renal and cardiac transplantation
66. Treatment and prognosis of post-transplant lymphoproliferative disease
67. A controlled trial of exercise rehabilitation after heart transplantation
68. Heart and heart-lung transplantation